Studies towards the synthesis of small molecule therapies for Metabolic Syndromes and Parkison's.
Start Date
August 2025
End Date
August 2025
Location
ALT 304
Abstract
The Mullins Lab is interested in the organic synthesis of medicinally relevant molecules. Specifically, this summer we worked on three projects. The first involved the synthesis of three tail pieces designed to be coupled with a corresponding head piece towards building benchmark compounds for testing as a Rev-Erb agonist. Rev-Erb agonists impact cardio and metabolic pathways, benefitting lipid levels and cardiac strength, allowing them to be used to treat metabolic disease. The second project involved developing a more efficient method of identification and evaluation of interaction domains on corepressors to indirectly enhance the abilities of a Liver X receptor alpha and beta (LXR a and b) inverse agonist drug using bioinformatic databases. Liver X Receptors (LXRs) play an important role in cholesterol metabolism and inflammation, making them an attractive target in drug discovery. And finally, we are investigating a multistep approach for the formation of a dopamine D2 receptor biased partial agonist. The dopamine D2 receptor is a target for some antiparkinsonian agents and antipsychotic drugs as well as some involvement with drugs that are associated with addiction. The progress toward each of these projects will be presented.
Studies towards the synthesis of small molecule therapies for Metabolic Syndromes and Parkison's.
ALT 304
The Mullins Lab is interested in the organic synthesis of medicinally relevant molecules. Specifically, this summer we worked on three projects. The first involved the synthesis of three tail pieces designed to be coupled with a corresponding head piece towards building benchmark compounds for testing as a Rev-Erb agonist. Rev-Erb agonists impact cardio and metabolic pathways, benefitting lipid levels and cardiac strength, allowing them to be used to treat metabolic disease. The second project involved developing a more efficient method of identification and evaluation of interaction domains on corepressors to indirectly enhance the abilities of a Liver X receptor alpha and beta (LXR a and b) inverse agonist drug using bioinformatic databases. Liver X Receptors (LXRs) play an important role in cholesterol metabolism and inflammation, making them an attractive target in drug discovery. And finally, we are investigating a multistep approach for the formation of a dopamine D2 receptor biased partial agonist. The dopamine D2 receptor is a target for some antiparkinsonian agents and antipsychotic drugs as well as some involvement with drugs that are associated with addiction. The progress toward each of these projects will be presented.
